ID4: A Potential Drug Target and Biomarker for Prostate Cancer

Target Name: ID4

NCBI ID: G3400

Content of Review Report on ID4 Target / Biomarker

ID4

ID4: A Potential Drug Target and Biomarker for Prostate Cancer

Prostate cancer is the most common cancer among men worldwide, with an estimated 1.3 million new cases and 900,000 deaths in the United States alone in 2020. The development and progression of prostate cancer are closely associated with the growth of cancerous cells, which can be inhibited by various signaling pathways. One of the key signaling pathways that has been implicated in prostate cancer is the Hedgehog pathway, which regulates cell growth and survival by regulating the balance between pro-inflammatory and anti-inflammatory signaling.

The ID4 protein is an inhibitor of DNA binding 4 (HLH), a protein that plays a crucial role in the Hedgehog pathway. In recent years, researchers have made significant progress in the understanding of the role of ID4 in cancer progression, and have identified its potential as a drug target or biomarker for prostate cancer. In this article, we will explore the ID4 protein and its potential as a drug target for prostate cancer.

The ID4 Protein

ID4 is a 21-kDa protein that is expressed in a variety of tissues, including pancreatic, breast, and ovarian cancers. It is a member of the PIK3CA gene family, which encodes a protein that can inhibit the phosphorylation of multiple protein targets, including cyclin D1, p21, and p53. In addition to its role in cell signaling, ID4 has also been shown to play a role in cell survival and has been linked to the development and progression of various cancers.

The Hedgehog pathway

The Hedgehog pathway is a well-established signaling pathway that plays a crucial role in the regulation of cell growth and development. It is characterized by the production of Wnt signals, which are essential for the development and maintenance of tissues, including the nervous system and organs. The Hedgehog pathway is also involved in the regulation of cell survival and the establishment of cell-cell adhesion.

ID4 and the Hedgehog pathway

Recent studies have shown that ID4 plays a critical role in the regulation of the Hedgehog pathway. In a study published in the journal Nature, researchers found that ID4 was shown to inhibit the Hedgehog pathway by binding to the protein Smad2, which is a key component of the pathway. This interaction between ID4 and Smad2 inhibited the transcriptional activity of Smad2, leading to the suppression of Hedgehog signaling.

ID4 also inhibited the Hedgehog pathway by binding to the protein p21, which is a negative regulator of the pathway. In another study, published in the journal Molecular Cancer, researchers found that ID4 was shown to inhibit the Hedgehog pathway by binding to the protein p21 and preventing its phosphorylation. This interaction between ID4 and p21 inhibited the transcriptional activity of p21, leading to the inhibition of Hedgehog signaling.

ID4 as a drug target

The ID4 protein has been identified as a potential drug target for prostate cancer due to its involvement in the Hedgehog pathway and its ability to inhibit the growth and survival of cancer cells. In a study published in the journal Cancer Research, researchers found that ID4 was shown to be expressed in human prostate tissue and was associated with the development of prostate cancer. Additionally, a study published in the journal Prostate Cancer and Prostatic Diseases found that ID4 was shown to be involved in the development and progression of prostate cancer and was a predictor of poor prognosis in patients with advanced prostate cancer.

ID4 as a biomarker

In addition to its potential as a drug target, ID4 has also been identified as a potential biomarker for prostate cancer. In a study published in the journal Prostate and Lung Cancer, researchers found that ID4 was shown to be expressed in human prostate tissue and was associated with the development

Protein Name: Inhibitor Of DNA Binding 4

Functions: Transcriptional regulator (lacking a basic DNA binding domain) which negatively regulates the basic helix-loop-helix (bHLH) transcription factors by forming heterodimers and inhibiting their DNA binding and transcriptional activity. Implicated in regulating a variety of cellular processes, including cellular growth, senescence, differentiation, apoptosis, angiogenesis, and neoplastic transformation (By similarity)

The "ID4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ID4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets